GlassScriptPhysician profile
Rodrigo Crespo
NPI 1609854090
$14,173.99
in general payments reported to CMS, 2019-2025
64 companies · $2,796 in 2025
The $2,796 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,471 · 2020: $1,295 · 2021: $1,873 · 2022: $1,992 · 2023: $1,836 · 2024: $1,910 · 2025: $2,796.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,542.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,542.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,178.81 | 2019-2025 | Vraylar, Linzess, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $1,168.16 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $982.74 | 2019-2025 | Ozempic, Wegovy, Saxenda |
| Lilly USA, LLC | $971.89 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $837.54 | 2019-2025 | Xarelto, Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $811.02 | 2019-2025 | Jardiance, Ofev, Synjardy |
| Amarin Pharma, INC. | $668.47 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $554.89 | 2019-2025 | Gardasil 9, Dificid, Verquvo |
| Glaxosmithkline, LLC. | $493.69 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Amgen INC. | $480.58 | 2019-2025 | Evenity, Repatha, Repatha |
| Nevro Corp. | $445.69 | 2020-2023 | Senza |
| Axsome Therapeutics, INC. | $416.11 | 2023-2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $292.36 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $261.15 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $252.26 | 2019-2025 |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodrigo Crespo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.